...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: ZEN-3694 Single Agent Trial Status

ZEN-3694 Single Agent Trial status now listed asĀ completed on ClinicalTrials.gov as of an updated posted 11/17/2017.

A Study of ZEN003694 in Patients With Metastatic Castration-Resistant Prostate Cancer

Share
New Message
Please login to post a reply